Professor ross smith
Professor Ross Smith is NanoMed cofounder and Co-CEO. He is also the head of preclinical and clinical operations of NanoMed. He is an Emeritus Professor at the Department of Surgery, University of Sydney, head of the Cancer Surgery Research Laboratory, Kolling Institute, and Chairman of the Cancer Surgery Research Foundation. He was the Immediate Past Chairman of the Australasian Pancreatic Club. Prof. Smith founded Cancer Surgery Research in 1999 and has raised over two million dollars to support research into improving outcomes for patients requiring surgery for cancer. He is a fellow at the Royal Australasian College of Surgeons, and past chairman of the Australian Society of Parenteral and Enteral Nutrition. He has been an Examiner for the Royal Australasian College of Surgeons and Royal Australian College of Emergency Medicine, and Sub Dean of the Northern Clinical School, University of Sydney. Prof. Smith’s team has discovered that apolipoprotein A-II is significantly reduced in the serum of a large group of patients with pancreatic cancer. This has lead them to focus their research on the role of apolipoprotein A-II high density lipid-like agents in pancreatic cancer treatment and diagnostics.